CGEM

Cullinan Therapeutics, Inc. - Common Stock (CGEM)

About Cullinan Therapeutics, Inc. - Common Stock (CGEM)

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Details

Daily high

$9.06

Daily low

$8.76

Price at open

$8.92

52 Week High

$21.82

52 Week Low

$6.85

Market cap

528.2M

Dividend yield

0.00%

Volume

183,913

Avg. volume

339,303

P/E ratio

-2.89

Cullinan Therapeutics, Inc. - Common Stock News